What to Expect at EADV Congress 2025, With Raj Chovatiya, MD, PhD, and Linda Stein Gold, MD

The European Academy of Dermatology and Venereology (EADV) Congress functions as both a yearly meeting of clinicians in dermatology and a place in which new late-breaking data and insightful sessions exploring dermatologic disease states help to redefine treatment approaches in the dermatology space.

The 2025 EADV Congress is set to take place in Paris, France, from September 17–20. The HCPLive team spoke about what to look forward to at EADV with Raj Chovatiya, MD, PhD, clinical associate professor at Rosalind Franklin University Chicago Medical School and director of the Center for Medical Dermatology and Immunology Research, and Linda Stein Gold, MD, the director of dermatology clinical research and division head of dermatology at the Henry Ford Health System.

"EADV is one of our biggest conferences of the year, and it's really a chance where a lot of the dermatology world comes together outside of the US, including some folks in the US too, to talk about what's happening in dermatology," Chovatiya said. "This year, beyond the usual of meeting my colleagues and catching up with people I don't get to see all that often, I'm really excited for a lot of the newer data presentations that are happening in the atopic dermatitis world."

Chovatiya highlighted that a number of late-breakers and oral presentations on some of the newer mechanisms of action that are being discussed in the dermatology world are to be included in the meeting. A list of late-breakers set to be presented at EADV can be found here.1

"I'm really excited to hear about some updates and some of the newer mechanisms, like the OX40 and OX40 ligand, as well as some even earlier phase mechanisms too, where we don't necessarily know what the future holds for their ability to become a commercialized drug," Chovatiya explained. "There's also long term updates, and some of the drugs that we're quite familiar with too, ones that we actually have available to us, both in a topical, oral and biologic realm as well."

Stein Gold also expressed her own excitement in anticipation of the EADV Congress 2025, echoing Chovatiya's sentiments regarding the variety of important data to be presented on treatments for conditions such as atopic dermatitis and psoriasis.

"This is always a very important meeting," Stein Gold said. "I'm interested in seeing what's going on in atopic dermatitis. We have some new drugs that are pretty much finishing up [their] phase 3 clinical trials. We have some long term efficacy and safety information on the OX40 drugs. So I'm really excited to see what's going on with that."

Stein Gold noted that there are data related to psoriasis treatments, including an oral, interleukin (IL)-23 medication for this prominent skin disease.

"We know we have the oral, IL-23 drug and this is very exciting," Stein Gold explained. "It could be a game changer for the oral therapy arena, for our psoriasis patients and a lot more. So I'm going to be there and I'll be taking notes. I'm sure I'm going to be taking home some important kernels of truth that will help make me a better clinician."

For updates on EADV coverage next week, view the latest conference coverage here.

The quotes contained in this interview were edited for clarity.

Raj Chovatiya has reported serving as an adviser, a consultant, a speaker or an investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CLn Skin Care, Dermavant, Eli Lilly, EMD Serono, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L'Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio and UCB.

Stein Gold has served as an investigator, advisor, and/or speaker for AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte Corporation, Ortho Dermatologics, Pfizer, Regeneron, and Sanofi and she has reported personal fees from AbbVie, Amgen, Arctis, Bristol MyerSquibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.

References

1. HCPLive Editorial Staff. EADV Congress 2025: Late-Breaking Trials Preview. HCPLive. September 9, 2025. Accessed September 12, 2025. https://www.hcplive.com/view/eadv-congress-2025-late-breaking-trials-preview.